On January 30, Jerome Seid, MD, FACP, testified during a hearing of the Michigan State Senate Committee on Health Policy and Human Services in support of SB 612, a bill that would make important reforms to prior authorization and step therapy protocols. Dr. Seid is a member of the Association for Clinical Oncology (ASCO) and past president of the Michigan Society of Hematology and Oncology (MSHO).
As a practicing hematologist and oncologist in Warren, Michigan, Dr. Seid provided first-hand experience to the Committee on how prior authorization impacts his patients.
"The prior authorization process in place today must be overhauled to eliminate treatment delays that inflict tremendous harm and needless suffering on our patients, and leaves physicians feeling accountable," said Dr. Seid. “This is dysfunction in our health care system that interferes with patient care and is in fact a barrier to care."
Payer-imposed utilization management practices, like prior authorization and step therapy, create delays in care that can have severe negative impacts on patients with cancer. ASCO has continued to advocate for reforms to prior authorization and step therapy to ensure that people with cancer get the care they need, when they need it.
Use ASCO’s ACT Network today to ask your representatives to help reduce delays in care.
Read the letter from MSHO and ASCO outlining how SB 612 would minimize care delays and improve outcomes for patients with cancer.
Read Dr. Seid’s prepared testimony.
Visit ASCO in Action for updates on this and other cancer policy priorities.